Research Analysts Offer Predictions for ACTU Q1 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for shares of Actuate Therapeutics in a research note issued to investors on Monday, April 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.21) per share for the quarter, up from their prior estimate of ($0.23). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at $0.04 EPS.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06.

ACTU has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Friday, March 27th. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $18.67.

Actuate Therapeutics Stock Performance

NASDAQ:ACTU opened at $2.15 on Wednesday. Actuate Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $11.99. The firm has a market cap of $50.98 million, a PE ratio of -2.05 and a beta of 0.85. The business has a 50 day moving average price of $3.06 and a 200-day moving average price of $5.30.

Institutional Investors Weigh In On Actuate Therapeutics

A number of large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC purchased a new position in shares of Actuate Therapeutics during the fourth quarter valued at approximately $190,000. Royal Bank of Canada lifted its stake in Actuate Therapeutics by 172.2% in the fourth quarter. Royal Bank of Canada now owns 35,263 shares of the company’s stock worth $215,000 after acquiring an additional 22,309 shares during the period. Barclays PLC boosted its holdings in Actuate Therapeutics by 68.6% in the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after acquiring an additional 6,081 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Actuate Therapeutics by 61.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,841 shares of the company’s stock valued at $146,000 after acquiring an additional 9,076 shares in the last quarter. Finally, State Street Corp increased its position in Actuate Therapeutics by 12.8% during the 4th quarter. State Street Corp now owns 56,290 shares of the company’s stock valued at $344,000 after purchasing an additional 6,395 shares during the period.

Actuate Therapeutics News Summary

Here are the key news stories impacting Actuate Therapeutics this week:

• Positive Sentiment: Nature Medicine peer‑reviewed Phase 2 results show elraglusib + chemo improved median overall survival to 10.1 vs 7.2 months (HR 0.62) and doubled 1‑year survival (44% vs 22%), boosting confidence in the drug’s clinical value and commercial potential. GlobeNewswire: Nature Medicine Publication
• Positive Sentiment: HC Wainwright reiterated a “Buy” and a $15 target while raising near‑term (Q1–Q4 2026) and FY2026–FY2028 EPS projections, indicating improved analyst expectations tied to the published data. AmericanBankingNews: HC Wainwright Note
• Positive Sentiment: Broad media coverage (Business Insider, Time, MSN) amplifies the clinical readout, increasing visibility among clinicians, patients and buy‑side investors—a common short‑term driver for small biotech names. Business Insider: Publication Announcement
• Neutral Sentiment: Institutional holders have been adding position sizes (Voss, Vanguard, BlackRock noted in recent filings), which can support liquidity and bid interest but may reflect longer‑term positioning rather than immediate monetization. QuiverQuant: Institutional and Fund Activity
• Negative Sentiment: Safety and tolerability: higher rates of Grade ≥3 neutropenia and anemia were observed with the combination; these AEs could complicate regulatory discussions or uptake and may require label/safety mitigation. GlobeNewswire: Safety Notes
• Negative Sentiment: Near‑term financing risk: company disclosure warns it needs additional capital beyond July 2026 to continue operations—this raises dilution risk that can pressure the stock despite positive clinical news. GlobeNewswire: Forward‑Looking / Cash Runway
• Negative Sentiment: Insider activity: a recent insider sale (reported) could be interpreted negatively by some investors and add selling pressure. QuiverQuant: Insider Trading

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.